Comment on 'KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer'

被引：2
|
作者：
Tougeron, D. [1 ]
Laurent-Puig, P. [2 ]
Zaanan, A. [2 ,3 ]
机构：
[1] Univ Poitiers Hosp, Dept Gastroenterol, Poitiers, France
[2] INSERM, UMR S775, Paris, France
[3] European Georges Pompidou Univ Hosp, AP HP, Dept Gastroenterol & Digest Oncol, Paris, France
来源：
BRITISH JOURNAL OF CANCER | 2014年 / 111卷 / 12期
关键词：
CIRCULATING MUTANT-DNA; ANTI-EGFR THERAPY; K-RAS MUTATIONS; ACQUIRED-RESISTANCE; CETUXIMAB; PCR;
D O I：
10.1038/bjc.2014.114
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：2379 / 2380
页数：3
相关论文
共 50 条
  • [41] Mutational status of plasma exosomal KRAS predicts outcome in patients with metastatic colorectal cancer
    Donatella Lucchetti
    Ina Valeria Zurlo
    Filomena Colella
    Claudio Ricciardi-Tenore
    Mariantonietta Di Salvatore
    Giampaolo Tortora
    Ruggero De Maria
    Felice Giuliante
    Alessandra Cassano
    Michele Basso
    Antonio Crucitti
    Ilaria Laurenzana
    Giulia Artemi
    Alessandro Sgambato
    Scientific Reports, 11
  • [42] Mutational status of plasma exosomal KRAS predicts outcome in patients with metastatic colorectal cancer
    Lucchetti, Donatella
    Zurlo, Ina Valeria
    Colella, Filomena
    Ricciardi-Tenore, Claudio
    Di Salvatore, Mariantonietta
    Tortora, Giampaolo
    De Maria, Ruggero
    Giuliante, Felice
    Cassano, Alessandra
    Basso, Michele
    Crucitti, Antonio
    Laurenzana, Ilaria
    Artemi, Giulia
    Sgambato, Alessandro
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [43] The MEK inhibitor selumetinib ([SEL], AZD6244, ARRY-142886) plus irinotecan (IRI) as second-line therapy for KRAS-mutated (KRASm) metastatic colorectal cancer (CRC).
    Hochster, Howard S.
    Messersmith, Wells A.
    O'Neil, Bert H.
    Groshen, Susan G.
    Lenz, Heinz-Josef
    Cohen, Deirdre Jill
    Denlinger, Crystal Shereen
    Gold, Philip Jordan
    Eckhardt, S. Gail
    Locker, Gershon Y.
    Ames, Patricia
    McKinley, Marti
    Leichman, Lawrence P.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [44] Genetic feature diversity of KRAS-mutated colorectal cancer and the negative association of DNA mismatch repair deficiency relevant mutational signatures with prognosis
    Shi, Ruichuan
    Cheng, Yu
    Wang, Jin
    Song, Na
    Chen, Ying
    Teng, Zan
    Xu, Ling
    Liu, Yunpeng
    Zhao, Xiaotian
    Ou, Qiuxiang
    Yang, Peng
    Ma, Rui
    Sun, Yiting
    Qu, Jinglei
    Qu, Xiujuan
    GENES & DISEASES, 2025, 12 (01)
  • [45] Benefit of EGFR-inhibition therapy for metastatic colorectal cancer patients with KRAS-mutated tumors and high plasma TIMP-I level: Results from the NORDIC VII study.
    Brunner, Nils
    Tarpgaard, Line Schmidt
    Christensen, Ib Jarle
    Moreira, Jose
    Guren, Tormod Kyrre
    Glimelius, Bengt
    Sorby, Halfdan
    Ikdahl, Tone
    Kure, Elin
    Tveit, Kjell Magne
    Nielsen, Hans Jorgen
    Pfeiffer, Per
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [46] Clinical Role of ASCT2 (SLC1A5) in KRAS-Mutated Colorectal Cancer
    Toda, Kosuke
    Nishikawa, Gen
    Iwamoto, Masayoshi
    Itatani, Yoshiro
    Takahashi, Ryo
    Sakai, Yoshiharu
    Kawada, Kenji
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2017, 18 (08)
  • [47] Cetuximab plus irinotecan after irinotecan failure in elderly metastatic colorectal cancer patients: Clinical outcome according to KRAS and BRAF mutational status
    Fornaro, Lorenzo
    Baldi, Giacomo Giulio
    Masi, Gianluca
    Allegrini, Giacomo
    Loupakis, Fotios
    Vasile, Enrico
    Cupini, Samanta
    Stasi, Irene
    Salvatore, Lisa
    Cremolini, Chiara
    Vincenzi, Bruno
    Santini, Daniele
    Tonini, Giuseppe
    Graziano, Francesco
    Ruzzo, Annamaria
    Canestrari, Emanuele
    Magnani, Mauro
    Falcone, Alfredo
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2011, 78 (03) : 243 - 251
  • [48] CETUXIMAB PLUS IRINOTECAN IN IRINOTECAN-RESISTANT ELDERLY METASTATIC COLORECTAL CANCER PATIENTS: CLINICAL OUTCOME ACCORDING TO KRAS AND BRAF MUTATIONAL STATUS
    Baldi, G.
    Fornaro, L.
    Masi, G.
    Vasile, E.
    Loupakis, F.
    Cupini, S.
    Allegrini, G.
    Marcucci, L.
    Stasi, I
    Santini, D.
    Tonini, G.
    Graziano, F.
    Ruzzo, A.
    Magnani, M.
    Falcone, A.
    ANNALS OF ONCOLOGY, 2010, 21 : 77 - 77
  • [49] KRAS Status as a Predictor of Chemotherapy Activity in Patients With Metastatic Colorectal Cancer
    Yarom, Nirit
    Gresham, Gillian
    Boame, Nana
    Jonker, Derek
    CLINICAL COLORECTAL CANCER, 2019, 18 (04) : E309 - E315
  • [50] Phase II study of linifanib in KRAS mutated metastatic refractory colorectal cancer
    Chan, E.
    Ayers, G. D.
    Goff, L.
    McClanahan, P.
    Holloway, M.
    Ciombor, K.
    Smith, S. J.
    Ancell, K.
    Cardin, D. B.
    Berlin, J.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S549 - S549
12345